Bloomlife

The company initially launched a direct-to-consumer wearable that allowed expectant mothers to track contractions from home. This first product was designed to automatically time, count, and measure contractions, sending the data to a smartphone app to help women understand their body's preparation for labor. After recognizing that healthcare providers were more focused on managing high-risk pregnancies, Bloomlife pivoted its strategy from a B2C to a B2B2C model in 2020. This involved shifting from a consumer wellness device to a clinical, prescription-based platform.

The core of Bloomlife's current offering is the FDA-cleared MFM-Pro, a prescription wearable patch that non-invasively monitors both maternal and fetal heart rates outside of a clinical setting. The platform is designed to replace manual processes and frequent in-clinic appointments with a comprehensive remote monitoring solution. It integrates with third-party devices to manage conditions like hypertension and diabetes, and also includes screenings for maternal mental health. The business model involves contracting with healthcare providers, such as health systems and private practices, who prescribe the service to their patients. Bloomlife manages the logistics, while the clinical teams interpret the data, which is integrated into their existing electronic medical record (EMR) workflows. Revenue is generated by sharing in the reimbursement that providers receive from insurance companies for remote patient monitoring services.